Matthew L. Posard, Director at HALOZYME THERAPEUTICS, INC. (HALO), sold 39,762 shares at $56.19 ($2.3M) on 2024-08-13, disclosed to the SEC on 2024-08-14.
Open-market sale of $2.3M HALO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $55.72 | 10,000 | $557K | 24.7% |
| 2 | $56.19 | 10,000 | $562K | 24.9% |
| 3 | $57.70 | 9,881 | $570K | 25.2% |
| 4 | $57.70 | 9,881 | $570K | 25.2% |
| Total | $56.82 avg | 39,762 | $2.3M | 100% |
| Filing → |
| HALO | SELL | 2024-06-13 | $1.0M | — | Filing → |
| HALO | SELL | 2022-12-06 | $1.7M | — | Filing → |
| NAUT | BUY | 2021-12-01 | $226K | — | Filing → |